PRISM HTLV-I/HTLV-II 06A53-48

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 01,05 report with the FDA on 2013-02-15 for PRISM HTLV-I/HTLV-II 06A53-48 manufactured by Abbott Laboratories.

Event Text Entries

[10575875] A retained kit of prism htlv-1 / htlv-2 reagent, list number 06a53-48 lot number 21105li00 was calibrated on one prism analyzer. To evaluate the performance with regard to specificity, replicates of an htlv-1 / htlv-2 specificity panel were tested. Results were within typical ranges and no false reactive results were obtained. A review of the human negative population, routinely evaluated during release testing, revealed no indications that the specificity of the reagent lot might be adversely affected. The mean value across all panel members for this lot number corresponds to the mean observed for all lot numbers. A review of complaint tracking and trending metrics was performed and identified no adverse trends in conjunction with the complaint issue currently under evaluation. Additionally, the performance was investigated by completing a review of manufacturing and testing records for the affected reagent lot. This review did not reveal any events or issues that may have impacted reagent performance in relation to the current complaint issue. The prism htlv-1/htlv-2 assay package insert contains information to address the current customer issue. Based on the results of the current evaluation, it has been determined that the prism htlv-1 / htlv-2 reagent, list number 06a53-48, lot number 21105li00, is performing acceptably.
Patient Sequence No: 1, Text Type: N, H10


[21261312] The customer reports an increase in repeat (b)(6) rates for the prism htlv-i/htlv-ii assay when they switched to reagent lot 21105li00. This occurred during the timeframe of (b)(6) 2013. This has resulted in donors who previously tested (b)(6) to now test (b)(6). The customer provided the following example: donor 2: initial (b)(6) result of (b)(6); repeat (b)(6) results of (b)(6). Previous (b)(6) result of (b)(6) on (b)(6) 2009 with reagent lot 71331hn00. To date, the customer has seen their repeat (b)(6) rate rise to 0. 05%. There is no further impact to donor management reported.
Patient Sequence No: 1, Text Type: D, B5


[21501331] An evaluation is in process. A follow-up report will be submitted when the evaluation is complete. This report is being filed on an international product, list number 06a53 that has a similar product distributed in the us, list number 06e50. (b)(4).
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number1415939-2013-00056
MDR Report Key2963314
Report Source01,05
Date Received2013-02-15
Date of Report2013-02-05
Date Mfgr Received2013-02-22
Device Manufacturer Date2012-11-01
Date Added to Maude2013-02-21
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactNOEMI ROMERO-KONDOS, RN BSN
Manufacturer Street100 ABBOTT PARK ROAD DEPT. 09B9, LCCP1-3
Manufacturer CityABBOTT PARK IL 600643537
Manufacturer CountryUS
Manufacturer Postal600643537
Manufacturer Phone847937-512
Manufacturer G1ABBOTT LABORATORIES
Manufacturer Street100 ABBOTT PARK ROAD
Manufacturer CityABBOTT PARK IL 60064350
Manufacturer CountryUS
Manufacturer Postal Code60064 3500
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NamePRISM HTLV-I/HTLV-II
Product CodeMTP
Date Received2013-02-15
Catalog Number06A53-48
Lot Number21105LI00
Device Expiration Date2013-12-14
OperatorOTHER
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerABBOTT LABORATORIES
Manufacturer Address100 ABBOTT PARK ROAD ABBOTT PARK IL 60064350 US 60064 3500


Patients

Patient NumberTreatmentOutcomeDate
10 2013-02-15

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.